亚博体育 开云移动端 熊猫体育 五大联赛直播在线观看 bob体育 爱游戏app 开云集团 xingkong 优发体育 乐虎体育 Kaiyun移动端 pp体育 星空体育 pg模拟器 五大联赛直播免费 意昂体育 有道翻译 Quickq下载 冠竞体育 开云官网app 爱游戏app 球速体育 开云集团 开云app 皇冠体育 爱游戏app 爱游戏 立博体育 九游娱乐 三亿体育 星空体育官网 爱游戏官网 爱游戏app 伟德体育 开云官网 杏彩体育 杏彩体育 意昂体育 乐鱼体育 升博体育 欧博登录 中欧体育 开云移动端 永利体育 芒果体育 ac米兰 开云集团 星空体育官方 利来体育 凤凰体育 Quickq下载 MK体育 九游 开云app ag真人百家乐 ag视讯 开云移动端 英亚体育 易倍体育 新利体育 爱游戏 九游体育 BB体育 中欧体育 yb体育 必一体育 微玩体育 ag真人娱乐 乐动体育 开云集团 bob体育 亚新体育 九博体育 实博体育 m8体育 千亿体育 亿搏体育 爱游戏app koko电竞 og真人视讯 开云中国官网 易倍体育 智博体育 爱游戏app 爱游戏 五大联赛免费直播 开云app移动端 开云集团 亚星官网 爱体育 伟德体育 雷火体育 九游体育app 宝威体育 速8体育 Kaiyun移动端 亚美体育 开云官网 开云app官网 ag真人娱乐 开云官网 开云手机版登录 开云app 星空体育 开云app官网 中欧体育 易胜博体育 爱游戏移动端 开云官方中国 开云体育 开云官方app 开云app官方 开云app 开云首页 完美体育 五大联赛直播在线观看 hth官方下载 新利体育 兴发体育 悟空体育 乐投体育 爱游戏app 华体会 kaiyun手机官网 ob体育 华体会 ob平台 开云体育 开云手机版官网 星空体育官网 鼎博体育 杏彩平台 云开体育 华体会 开云app 开云手机版 亿德体育 现金体育 九游app 爱思助手 奇异果体育 五大联赛免费直播 九游app kaiyun手机版 英皇体育 开云中国官网 爱体育 吉祥体育 xingkong 开云集团 华体会 JM体育 华体会 开云官方网址 星空体育 开云 爱思助手 开云 西甲赛程 开云官方中国 九球体育 开云移动端app 开云中国官网 爱游戏app移动端 星空体育官方 开云体育 乐鱼官网 大发体育 光速体育 开云手机版 开云app官网 有道翻译 开云集团 星空体育 爱游戏app移动端 完美体育 星空体育app下载 xingkong 五大联赛直播免费 开云移动端 九游体育app 爱游戏app 乐鱼官网 五大联赛直播平台 开云手机版 捷报体育 极速体育 万象城体育 乐动体育 世博体育 ac米兰 IM体育官网 星空体育 开云体育 开云体育 极速体育 开云app网址 乐鱼体育 雷竞技官网 米乐体育
EMBL Ventures https://www.embl-ventures.com/ Wed, 14 May 2025 11:05:36 +0000 en-US hourly 1 https://www.embl-ventures.com/wp-content/uploads/2020/11/cropped-EV_EVP_icon-32x32.jpg EMBL Ventures https://www.embl-ventures.com/ 32 32 Topas Therapeutics’ TPM502 Achieves Gluten-specific Tolerance lnduction https://www.embl-ventures.com/news/2025/05/topas-therapeutics-tpm502-achieves-gluten-specific-tolerance-lnduction/ Tue, 06 May 2025 11:04:29 +0000 https://www.embl-ventures.com/?p=694 The post Topas Therapeutics’ TPM502 Achieves Gluten-specific Tolerance lnduction appeared first on EMBL Ventures.

]]> The post Topas Therapeutics’ TPM502 Achieves Gluten-specific Tolerance lnduction appeared first on EMBL Ventures.

]]> Topas Therapeutics Announces Positive Topline Results from Phase 2a Trial https://www.embl-ventures.com/news/2024/10/topas-therapeutics-announces-positive-topline-results-from-phase-2a-trial/ Tue, 15 Oct 2024 15:00:49 +0000 https://www.embl-ventures.com/?p=690 The post Topas Therapeutics Announces Positive Topline Results from Phase 2a Trial appeared first on EMBL Ventures.

]]> The post Topas Therapeutics Announces Positive Topline Results from Phase 2a Trial appeared first on EMBL Ventures.

]]> Topas Therapeutics Appoints Hugo Fry as CEO https://www.embl-ventures.com/news/2024/05/topas-therapeutics-appoints-hugo-fry-as-ceo/ Tue, 07 May 2024 15:01:52 +0000 https://www.embl-ventures.com/?p=686 The post Topas Therapeutics Appoints Hugo Fry as CEO appeared first on EMBL Ventures.

]]> The post Topas Therapeutics Appoints Hugo Fry as CEO appeared first on EMBL Ventures.

]]> Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP https://www.embl-ventures.com/news/2024/02/allecra-therapeutics-announces-u-s-fda-approval-for-exblifep/ Tue, 27 Feb 2024 16:39:17 +0000 https://www.embl-ventures.com/?p=681 The post Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP appeared first on EMBL Ventures.

]]> The post Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP appeared first on EMBL Ventures.

]]> Allecra Licensor Advanz receives positive CHMP opinion for EXBLIFEP https://www.embl-ventures.com/news/2024/01/allecra-licensor-advanz-receives-positive-chmp-opinion-for-exblifep/ Tue, 30 Jan 2024 12:14:55 +0000 https://www.embl-ventures.com/?p=677 The post Allecra Licensor Advanz receives positive CHMP opinion for EXBLIFEP appeared first on EMBL Ventures.

]]> The post Allecra Licensor Advanz receives positive CHMP opinion for EXBLIFEP appeared first on EMBL Ventures.

]]> Allecra Therapeutics Submits New Drug Application to the U.S. FDA https://www.embl-ventures.com/news/2023/06/allecra-therapeutics-submits-new-drug-application-to-the-u-s-fda/ Tue, 27 Jun 2023 08:42:09 +0000 https://www.embl-ventures.com/?p=665 The post Allecra Therapeutics Submits New Drug Application to the U.S. FDA appeared first on EMBL Ventures.

]]> The post Allecra Therapeutics Submits New Drug Application to the U.S. FDA appeared first on EMBL Ventures.

]]> Allecra Publishes Final Phase 3 ALLIUM Data in JAMA https://www.embl-ventures.com/news/2022/10/allecra-publishes-final-phase-3-allium-data-in-jama/ Wed, 05 Oct 2022 10:33:38 +0000 https://www.embl-ventures.com/?p=661 The post Allecra Publishes Final Phase 3 ALLIUM Data in JAMA appeared first on EMBL Ventures.

]]> The post Allecra Publishes Final Phase 3 ALLIUM Data in JAMA appeared first on EMBL Ventures.

]]> Topas Therapeutics Appoints Cristina de Min, M.D. as Chief Medical Officer https://www.embl-ventures.com/news/2022/02/topas-therapeutics-appoints-cmo/ Tue, 15 Feb 2022 16:26:38 +0000 https://www.embl-ventures.com/?p=638 The post Topas Therapeutics Appoints Cristina de Min, M.D. as Chief Medical Officer appeared first on EMBL Ventures.

]]> The post Topas Therapeutics Appoints Cristina de Min, M.D. as Chief Medical Officer appeared first on EMBL Ventures.

]]> Allecra Therapeutics and Advanz Pharma Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe https://www.embl-ventures.com/news/2022/01/allecra-therapeutics-and-advanz-pharma-sign-exclusive-license-and-supply-agreement-for-allecras-antibiotic-cefepime-enmetazobactam-in-europe/ Thu, 13 Jan 2022 15:11:23 +0000 https://www.embl-ventures.com/?p=631 The post Allecra Therapeutics and Advanz Pharma Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe appeared first on EMBL Ventures.

]]> The post Allecra Therapeutics and Advanz Pharma Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe appeared first on EMBL Ventures.

]]> BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies https://www.embl-ventures.com/news/2022/01/biontech-and-crescendo/ Wed, 12 Jan 2022 17:18:42 +0000 https://www.embl-ventures.com/?p=626 The post BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies appeared first on EMBL Ventures.

]]> The post BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies appeared first on EMBL Ventures.

]]>